Physician profile
Katherine Wu
NPI 1033347729
$1,086.08
in general payments reported to CMS, 2019-2025
16 companies · $49.86 in 2025
The $49.86 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $109 · 2021: $56.48 · 2022: $157 · 2023: $193 · 2024: $225 · 2025: $49.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $324.74 | 2022-2025 | |
| Glaxosmithkline, LLC. | $141.00 | 2020-2023 | Bexsero |
| Alexion Pharmaceuticals, INC. | $137.50 | 2019 | |
| Sobi, INC | $99.79 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $80.99 | 2019-2021 | |
| Cranial Technologies, INC | $65.94 | 2024 | Doc Band |
| Sanofi Pasteur INC. | $41.04 | 2023-2024 | |
| Welch Allyn | $40.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.65 | 2019 | |
| Kaleo, INC. | $23.35 | 2024 | Auvi-Q |
| Organon LLC | $18.91 | 2025 | |
| Qiagen, LLC | $17.76 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.73 | 2024 | Ycanth |
| Ethicon US, LLC | $15.29 | 2023 | Megadyne |
| Tris Pharma INC | $13.17 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.